PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1355336-0 1992 Overexpression of erbB-2 protein in gastric adenocarcinoma--a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. Fluorouracil 113-117 erb-b2 receptor tyrosine kinase 2 Homo sapiens 18-24 10327070-5 1999 One drug, 5-fluorouracil, was found to be antagonistic with rhuMAb HER2 in vitro (CI=2.87, P=0.0001). Fluorouracil 10-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-71 9667258-2 1998 METHODS: We determined plasma levels of c-erbB-2 in 79 stages II and III breast cancer patients who received cyclophosphamide, methotrexate, and flourouracil (CMF)/cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP) chemotherapy. Fluorouracil 196-208 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-48 7896881-8 1995 ErbB-2-transformed MCF10-A cells responded to mitomycin, cisplatin, and 5-Fl-uracil, suggesting that signaling from activated ErbB-2 enhances the cells ability to respond to DNA damage. Fluorouracil 72-83 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-6 7896881-8 1995 ErbB-2-transformed MCF10-A cells responded to mitomycin, cisplatin, and 5-Fl-uracil, suggesting that signaling from activated ErbB-2 enhances the cells ability to respond to DNA damage. Fluorouracil 72-83 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-132 9110342-2 1997 HER2 overexpression has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluoruracil) and anthracyclines. Fluorouracil 170-181 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 7908410-9 1994 CONCLUSIONS: There is a significant dose-response effect of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in patients with overexpression of c-erbB-2 but not in patients with no c-erbB-2 expression or minimal c-erbB-2 expression. Fluorouracil 122-134 erb-b2 receptor tyrosine kinase 2 Homo sapiens 170-178 7908410-9 1994 CONCLUSIONS: There is a significant dose-response effect of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in patients with overexpression of c-erbB-2 but not in patients with no c-erbB-2 expression or minimal c-erbB-2 expression. Fluorouracil 122-134 erb-b2 receptor tyrosine kinase 2 Homo sapiens 207-215 7908410-9 1994 CONCLUSIONS: There is a significant dose-response effect of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in patients with overexpression of c-erbB-2 but not in patients with no c-erbB-2 expression or minimal c-erbB-2 expression. Fluorouracil 122-134 erb-b2 receptor tyrosine kinase 2 Homo sapiens 207-215 7584078-7 1994 We have constructed a chimeric minigene consisting of the proximal ERBB2 promoter linked to the gene encoding cytosine deaminase, an enzyme that can deaminate the prodrug 5-fluorocytosine (5-FC) to form cytotoxic 5-fluorouracil (5-FU). Fluorouracil 213-227 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 7584078-7 1994 We have constructed a chimeric minigene consisting of the proximal ERBB2 promoter linked to the gene encoding cytosine deaminase, an enzyme that can deaminate the prodrug 5-fluorocytosine (5-FC) to form cytotoxic 5-fluorouracil (5-FU). Fluorouracil 229-233 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 1355336-4 1992 However, erbB-2 overexpression was an indicator for poor disease free survival (p = 0.0474), local relapse free survival (p = 0.0293), and overall survival (p = 0.0310) of the patients treated with surgery only (N = 51), while it did not show any effect on outcome of patients treated with 5-FU plus Doxorubicin (FA) as adjuvant chemotherapy (N = 58). Fluorouracil 290-294 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-15 1351538-12 1992 CONCLUSION: We conclude that tumors with overexpression of the c-erbB-2 oncogene are less responsive to cyclophosphamide, methotrexate, and fluorouracil (CMF)-containing adjuvant therapy regimens than those with a normal amount of gene product. Fluorouracil 140-152 erb-b2 receptor tyrosine kinase 2 Homo sapiens 63-71 33720069-5 2021 In human epidermal growth factor receptor 2 (HER2)-positive oesophago-gastric adenocarcinoma, a phase II trial showed improved DFS when pertuzumab and trastuzumab were added to perioperative FLOT (5-fluorouracil/leucovorin, oxaliplatin, docetaxel). Fluorouracil 197-211 erb-b2 receptor tyrosine kinase 2 Homo sapiens 45-49 34312098-2 2022 The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). Fluorouracil 159-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 285-319 34312098-2 2022 The aim of this study is to compare the efficacy and late-onset cardiac toxicity of neoadjuvant chemotherapy regimens, trastuzumab plus paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (PH-FECH) versus trastuzumab plus docetaxel and carboplatin (TCH), for human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). Fluorouracil 159-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 330-334 34710829-0 2021 Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells. Fluorouracil 20-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 86-90 32235305-1 2020 Trastuzumab in combination with a platinum and fluorouracil is the treatment of choice for patients with advanced human epidermal growth factor receptor 2 (HER2) positive gastric cancer and gastroesophageal junction (GEJ) cancer. Fluorouracil 47-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 120-154 32727638-0 2020 Pyrotinib Sensitizes 5-Fluorouracil-resistant HER2+ Breast 4 Cancer Cells to 5-Fluorouracil. Fluorouracil 21-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 46-50 32727638-0 2020 Pyrotinib Sensitizes 5-Fluorouracil-resistant HER2+ Breast 4 Cancer Cells to 5-Fluorouracil. Fluorouracil 77-91 erb-b2 receptor tyrosine kinase 2 Homo sapiens 46-50 32235305-1 2020 Trastuzumab in combination with a platinum and fluorouracil is the treatment of choice for patients with advanced human epidermal growth factor receptor 2 (HER2) positive gastric cancer and gastroesophageal junction (GEJ) cancer. Fluorouracil 47-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 156-160 31918721-4 2020 RESULTS: In this study, Engineered exosomes were exploited to simultaneously deliver an anticancer drug 5-FU and miR-21 inhibitor oligonucleotide (miR-21i) to Her2 expressing cancer cells. Fluorouracil 104-108 erb-b2 receptor tyrosine kinase 2 Homo sapiens 159-163 32014926-2 2020 MATERIALS AND METHODS: Calcitriol and tacalcitol were used to increase the antiproliferative effect of 5-fluorouracil against the following human breast cancer cell lines: MCF-7, T47D, BT-474 (luminal); JIMT-1, SKBR-3 (HER2-enriched); MDA-MB-231 (triple-negative/basal-B), and non-malignant MCF-10A breast epithelial cells. Fluorouracil 103-117 erb-b2 receptor tyrosine kinase 2 Homo sapiens 219-223 30124494-1 2019 BACKGROUND: Combination therapy with fluorouracil, platinum, and trastuzumab (Tmab) is the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, and there is currently no established second-line therapy. Fluorouracil 37-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-156 31019975-0 2019 Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo. Fluorouracil 30-44 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-93 31019975-9 2019 Western blot analysis showed that gemcitabine/5-fluorouracil increased the expressions of total and phosphorylated forms of HER2, thus enhancing the cytotoxicity of trastuzumab. Fluorouracil 46-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 124-128 31019975-12 2019 Our in vivo and in vitro data suggest that sequential therapy with gemcitabine/5-fluorouracil followed by trastuzumab represents a novel and promising therapeutic strategy against HER2-negative GBC. Fluorouracil 79-93 erb-b2 receptor tyrosine kinase 2 Homo sapiens 180-184 31019975-13 2019 The upregulation of phosphorylated HER2 and phosphorylated-AKT induced by gemcitabine/5-fluorouracil treatment shows that HER2/AKT pathway is triggered. Fluorouracil 86-100 erb-b2 receptor tyrosine kinase 2 Homo sapiens 35-39 31019975-13 2019 The upregulation of phosphorylated HER2 and phosphorylated-AKT induced by gemcitabine/5-fluorouracil treatment shows that HER2/AKT pathway is triggered. Fluorouracil 86-100 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-126 30124494-1 2019 BACKGROUND: Combination therapy with fluorouracil, platinum, and trastuzumab (Tmab) is the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, and there is currently no established second-line therapy. Fluorouracil 37-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-162 30056083-3 2018 Compared to 5-FU alone, MH synergistically enhanced the chemotherapeutic effects of 5-FU, by reducing cell proliferation through the suppression of EGFR, HER2, p-Akt and p-mTOR expression, and promoting apoptosis by the modulation pro-apoptotic (p53, Bax, Cyto c, FasL caspase-3, -8, -9 and cleave-PARP) and anti-apoptotic (Bcl-2) markers. Fluorouracil 84-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 154-158 29451302-1 2018 According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. Fluorouracil 106-120 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-205 29451302-1 2018 According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. Fluorouracil 106-120 erb-b2 receptor tyrosine kinase 2 Homo sapiens 207-211 29451302-1 2018 According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. Fluorouracil 122-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-205 29451302-1 2018 According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. Fluorouracil 122-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 207-211 29845287-5 2018 Western blot analysis further demonstrated that the phosphorylation of Akt was inhibited by lapatinib, and the results of the MTT assay revealed that the combination of lapatinib with either 5-FU or gemcitabine demonstrated synergistic antitumor effects, whereas a combinatory treatment of lapatinib with epirubicin, a typical anthracycline drug, exhibited antagonistic antitumor effects in HER2-positive breast cancer cells. Fluorouracil 191-195 erb-b2 receptor tyrosine kinase 2 Homo sapiens 391-395 26623038-1 2015 In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU) plus cisplatin, significantly increased overall survival compared with chemotherapy alone (ToGA trial). Fluorouracil 230-244 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-60 28160563-8 2017 MiR-3622b-5p turned ERBB2-positive cancer cells more vulnerable to the apoptosis induced by cisplatin and 5-fluorouracil. Fluorouracil 106-120 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-25 26810644-9 2016 RESULTS: Compared to PIT alone, the combination of HER2-targeted PIT and 5-FU rapidly induced significant cytotoxicity in both the short-term and long-term cytotoxicity assays. Fluorouracil 73-77 erb-b2 receptor tyrosine kinase 2 Homo sapiens 51-55 26810644-13 2016 CONCLUSIONS: PIT in combination with 5-FU resulted in enhanced antitumor effects compared to PIT alone for HER2-expressing human gastric cancer in vitro and in vivo. Fluorouracil 37-41 erb-b2 receptor tyrosine kinase 2 Homo sapiens 107-111 26345461-1 2015 BACKGROUND: Neoadjuvant chemotherapy (NAC) with taxanes followed by fluorouracil, epirubicin, and cyclophosphamide (FEC), and concurrent trastuzumab is a potent regimen for HER2 over-expressing breast cancer. Fluorouracil 68-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 173-177 28494379-4 2017 In this study, we analyzed the main intermolecular interactions between a drug used in the cancer treatment (5-fluorouracil) and HER2. Fluorouracil 109-123 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-133 28494379-6 2017 From the docking simulations it was possible to analyze the interactions that occur between some residues in the binding site of HER2 and 5-FU. Fluorouracil 138-142 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-133 28494379-11 2017 Therefore, this study allowed a careful evaluation on the main structural, spectroscopic and electronic properties involved in the interaction between 5-FU and HER2, an important biological complex related to the cancer treatment. Fluorouracil 151-155 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-164 28850174-23 2017 Testing all patients for HER-2 status may help to identify patients with HER-2-positive tumours, for whom, in the absence of contraindications, trastuzumab in combination with capecitabine or 5-FU in combination with cisplatin has been shown to be beneficial. Fluorouracil 192-196 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-30 28850174-23 2017 Testing all patients for HER-2 status may help to identify patients with HER-2-positive tumours, for whom, in the absence of contraindications, trastuzumab in combination with capecitabine or 5-FU in combination with cisplatin has been shown to be beneficial. Fluorouracil 192-196 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-78 28850174-24 2017 For HER-2 negative people, all different two-and three-drug combinations including irinotecan, docetaxel, oxaliplatin or oral 5-FU prodrugs are valid treatment options for advanced gastric cancer, and consideration of the side effects of each regimen is essential in the treatment decision. Fluorouracil 126-130 erb-b2 receptor tyrosine kinase 2 Homo sapiens 4-9 27626067-5 2016 The patient was treated with trastuzumab combined with infusional 5-fluorouracil and leucovorin based on the presence of ERBB2 p.L755S kinase mutation in the tumor and based on the available evidence at the time when standard treatment options had been exhausted. Fluorouracil 66-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 121-126 26623038-1 2015 In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU) plus cisplatin, significantly increased overall survival compared with chemotherapy alone (ToGA trial). Fluorouracil 230-244 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-66 26623038-1 2015 In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5-fluorouracil (5-FU) plus cisplatin, significantly increased overall survival compared with chemotherapy alone (ToGA trial). Fluorouracil 246-250 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-66 25871911-10 2015 These surprising findings in a group of phenotypically similar patients with ER-positive, endocrine therapy-pretreated, HER2-negative metastases, are supported by preclinical data showing that sensitivity to 5-fluorouracil is enhanced by deficiencies in chromatin remodeling and homologous recombination genes. Fluorouracil 208-222 erb-b2 receptor tyrosine kinase 2 Homo sapiens 120-124 21080742-4 2010 In patients with HER2-positive metastatic gastric cancer (n = 584), median overall survival (primary endpoint) was significantly longer for recipients of intravenous trastuzumab plus chemotherapy (comprising cisplatin and either fluorouracil or capecitabine) than in those receiving chemotherapy alone in the ToGA trial. Fluorouracil 229-241 erb-b2 receptor tyrosine kinase 2 Homo sapiens 17-21 25744576-1 2015 BACKGROUND: Trastuzumab with 5-fluorouracil (5-FU) and cisplatin offers prolonged survival in patients with HER2-overexpressing advanced gastric cancer (AGC) and advanced gastro-oesophageal junction cancer (AGOJ). Fluorouracil 29-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-112 25744576-1 2015 BACKGROUND: Trastuzumab with 5-fluorouracil (5-FU) and cisplatin offers prolonged survival in patients with HER2-overexpressing advanced gastric cancer (AGC) and advanced gastro-oesophageal junction cancer (AGOJ). Fluorouracil 45-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-112 25901146-4 2015 The 1F2-coupled 5-FU-loaded BSA nanoparticles interacted with nearly all HER2 receptors available on the surface of HER2-positive SKBR3 cells. Fluorouracil 16-20 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-77 25901146-4 2015 The 1F2-coupled 5-FU-loaded BSA nanoparticles interacted with nearly all HER2 receptors available on the surface of HER2-positive SKBR3 cells. Fluorouracil 16-20 erb-b2 receptor tyrosine kinase 2 Homo sapiens 116-120 25901146-9 2015 This novel system can efficiently be employed for targeted delivery of 5-FU to HER2-positive cancerous cells. Fluorouracil 71-75 erb-b2 receptor tyrosine kinase 2 Homo sapiens 79-83 25778705-7 2015 In the HER2+ cohort (n = 88), 50% of patients demonstrated possible benefit from a combination of trastuzumab with 5FU/capecitabine based on concurrent low TS, 53% with irinotecan (high TOPO1), 63% with cisplatin (low ERCC1) and 55% with gemcitabine (low RRM1). Fluorouracil 115-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 7-11 22614071-0 2012 Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. Fluorouracil 58-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 22614071-6 2012 While the mTOR inhibitor everolimus enhanced fluorouracil-induced apoptosis in both HER2-amplified cell lines, this was not the case in the gastric cancer cell lines without HER2 amplification. Fluorouracil 45-57 erb-b2 receptor tyrosine kinase 2 Homo sapiens 84-88 22614071-8 2012 In summary, inhibition of the mTOR/S6K signal may be a key molecular event in enhancing fluorouracil-induced apoptosis specifically in gastric cancer cells with HER2 amplification. Fluorouracil 88-100 erb-b2 receptor tyrosine kinase 2 Homo sapiens 161-165 22222640-1 2012 Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry 3+ or immunohistochemistry 2+/fluorescence in situ hybridization-positive or immunohistochemistry 2+/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Fluorouracil 48-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 163-197 22293713-9 2012 The potentiation effect of combined treatment was associated with downregulation of EGFR and HER2 signaling pathways because data from western blot analysis showed that lapatinib in combination with 5-Fu markedly reduced the phosphorylation of EGFR and HER2, and inhibited the activation of downstream signaling molecules, such as AKT and ERK. Fluorouracil 223-227 erb-b2 receptor tyrosine kinase 2 Homo sapiens 105-109 22293713-9 2012 The potentiation effect of combined treatment was associated with downregulation of EGFR and HER2 signaling pathways because data from western blot analysis showed that lapatinib in combination with 5-Fu markedly reduced the phosphorylation of EGFR and HER2, and inhibited the activation of downstream signaling molecules, such as AKT and ERK. Fluorouracil 223-227 erb-b2 receptor tyrosine kinase 2 Homo sapiens 289-293 22293713-11 2012 These results indicate that the combination of the lapatinib and 5-Fu is a promising treatment option for esophageal carcinoma with HER2 amplification. Fluorouracil 77-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 156-160 21985855-0 2011 Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). Fluorouracil 132-146 erb-b2 receptor tyrosine kinase 2 Homo sapiens 39-43 24472145-5 2014 METHODS: We evaluated the expression of HER-2/neu protein in gastric cell lines by FACS and then comparing the cytotoxicity in chemotherapeutics (doxorubicin, cisplatin, paclitaxel, 5-FU) alone and in combination with Herceptin according to the expression of HER-2/neu protein by MTT assay. Fluorouracil 182-186 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-49 23708506-8 2013 Lapatinib in combination with 5-FU had more potent antitumor effects in the primary ESCC xenograft model, and markedly reduced the phosphorylation of EGFR and HER2, compared with lapatinib alone or in combination with oxaliplatin. Fluorouracil 30-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 159-163 22534547-2 2012 METHODOLOGY: Twenty-two meta-static gastric cancer patients with HER2 over-expression (3+ by immunohistochemistry or HER2 amplification by fluorescence in situ hybridization) previously treated with 5-fluorouracil-based chemotherapy were eligible. Fluorouracil 199-213 erb-b2 receptor tyrosine kinase 2 Homo sapiens 65-69 23422737-10 2012 HM781-36B combined with 5-fluorouracil, cisplatin, paclitaxel, or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells. Fluorouracil 24-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 124-128 23422737-10 2012 HM781-36B combined with 5-fluorouracil, cisplatin, paclitaxel, or gemcitabine showed a synergistic inhibitory effect on the HER2-amplified and on some of the HER2-nonamplified breast cancer cells. Fluorouracil 24-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-162 21712253-6 2011 Furthermore, we found that HER2 overexpression led to an increased resistance of MCF7 cells to multiple antitumor drugs such as paclitaxel (Taxol), cisplatin (DDP), etoposide (VP-16), adriamycin (ADM), mitoxantrone (MX), and 5-fluorouracil (5-FU). Fluorouracil 225-239 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-31 21712253-6 2011 Furthermore, we found that HER2 overexpression led to an increased resistance of MCF7 cells to multiple antitumor drugs such as paclitaxel (Taxol), cisplatin (DDP), etoposide (VP-16), adriamycin (ADM), mitoxantrone (MX), and 5-fluorouracil (5-FU). Fluorouracil 241-245 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-31 21160270-0 2010 [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. Fluorouracil 112-124 erb-b2 receptor tyrosine kinase 2 Homo sapiens 11-15 20238327-19 2010 Two and three-drug regimens including 5-FU, cisplatin, with or without an anthracycline, as well as irinotecan or docetaxel-containing regimens are reasonable treatment options for HER-2 negative patients. Fluorouracil 38-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 181-186 20682991-8 2010 CONCLUSION: 5-FU is more effective in combination with the TS-reducing action of Rap, even for highly HER2-expressing breast cancer cells. Fluorouracil 12-16 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-106 20811704-9 2010 The activity of Akt3/PKBgamma was inhibited with 5-FU alone and trastuzumab, indicating that trastuzumab may inhibit colon cancer growth through ErbB2-Akt3/PKBgamma signaling. Fluorouracil 49-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-150 19885610-2 2009 The MDA-MB-453 cells, which have been shown to overexpress ErbB2, were resistant to 5-fluorouracil; 5-fluorouracil exhibited a small dose-dependent anti-proliferative effect, with an IC50 of 90 microM. Fluorouracil 100-114 erb-b2 receptor tyrosine kinase 2 Homo sapiens 59-64 19885610-9 2009 Taken together, our results suggest that 5-fluorouracil acts synergistically with apigenin inhibiting cell growth and inducing apoptosis via the down-regulation of ErbB2 expression and Akt signaling. Fluorouracil 41-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 164-169 19885610-7 2009 The level of ErbB2 was unchanged by 5-fluorouracil alone but was drastically reduced in cells treated with 5-fluorouracil plus apigenin. Fluorouracil 36-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 13-18 19885610-7 2009 The level of ErbB2 was unchanged by 5-fluorouracil alone but was drastically reduced in cells treated with 5-fluorouracil plus apigenin. Fluorouracil 107-121 erb-b2 receptor tyrosine kinase 2 Homo sapiens 13-18 18390970-0 2008 Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. Fluorouracil 107-119 erb-b2 receptor tyrosine kinase 2 Homo sapiens 33-39 19470942-1 2009 PURPOSE We have demonstrated that patients with HER2-amplified tumors derive more benefit from higher doses of doxorubicin-containing chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil [CAF]). Fluorouracil 183-195 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-52 18390970-0 2008 Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. Fluorouracil 107-119 erb-b2 receptor tyrosine kinase 2 Homo sapiens 41-46 18390970-2 2008 Results from a previous study from the Cancer and Leukemia Group B (CALGB 8541) demonstrated an interaction between ErbB-2 and increasing dose of adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) chemotherapy. Fluorouracil 190-202 erb-b2 receptor tyrosine kinase 2 Homo sapiens 116-122 17885815-6 2008 Methotrexate (MTX), 5-florouracil (5-Fu), and cisplatin (CDDP) are commonly used for breast carcinoma treatment in clinics; however, patients with HER2/neu overexpression exhibit resistance to these anticancer drugs. Fluorouracil 20-33 erb-b2 receptor tyrosine kinase 2 Homo sapiens 147-155 18082672-0 2008 The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. Fluorouracil 93-107 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-49 18082672-7 2008 Mechanistic studies demonstrated that the 5-FU plus scFv23/TNF combination specifically resulted in a down-regulation of HER-2/neu, p-Akt and Bcl-2 and up-regulation of TNF-R1. Fluorouracil 42-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 121-130 18082672-9 2008 Delivery of the cytokine TNF to HER-2/neu expressing pancreatic tumor cells, which are inherently resistant to TNF using scFv23/TNF may be an effective therapy for pancreatic cancer especially when utilized in combination with 5-FU. Fluorouracil 227-231 erb-b2 receptor tyrosine kinase 2 Homo sapiens 32-37 17885815-6 2008 Methotrexate (MTX), 5-florouracil (5-Fu), and cisplatin (CDDP) are commonly used for breast carcinoma treatment in clinics; however, patients with HER2/neu overexpression exhibit resistance to these anticancer drugs. Fluorouracil 35-39 erb-b2 receptor tyrosine kinase 2 Homo sapiens 147-155 16137437-0 2005 HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. Fluorouracil 114-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 17200359-1 2007 PURPOSE: Findings from our previously published phase III randomized trial showed a high pathologic complete remission (CR) rate in patients with human epidermal growth factor receptor 2-positive breast cancer after the concurrent administration of trastuzumab and paclitaxel, followed by concurrent trastuzumab and 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) preoperative chemotherapy. Fluorouracil 316-330 erb-b2 receptor tyrosine kinase 2 Homo sapiens 152-186 18337622-4 2007 RESULTS: Statistically significant associations were found between 5-fluorouracil (5-FU) sensitivity in HDRA and HER-2 mRNA expression level (p = 0.0030). Fluorouracil 67-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 113-118 18337622-4 2007 RESULTS: Statistically significant associations were found between 5-fluorouracil (5-FU) sensitivity in HDRA and HER-2 mRNA expression level (p = 0.0030). Fluorouracil 83-87 erb-b2 receptor tyrosine kinase 2 Homo sapiens 113-118 16243820-4 2005 RNA expression levels of 5-FU metabolism-associated genes thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase, MAP7, and ELF3, of platinum- and taxane-related genes caldesmon, ERCC1, ERCC4, HER-2/neu, and GADD45, and of multidrug resistance gene MRP1 were determined using real-time reverse transcriptase-PCR. Fluorouracil 25-29 erb-b2 receptor tyrosine kinase 2 Homo sapiens 254-263 16315942-1 2005 PURPOSE: We report two patients with refractory recurrent breast cancer (HER2/neu: +) postoperatively, who had failed response to the available conventional chemotherapy of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and docetaxel, etc. Fluorouracil 208-222 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-77 15640503-0 2004 Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. Fluorouracil 135-147 erb-b2 receptor tyrosine kinase 2 Homo sapiens 45-50 15640503-7 2004 CONCLUSION: High dose fluorouracil/leucovorin-based chemotherapy may have the potential to reverse the adverse effects resulting from erbB2 gene amplification in gastric cancer. Fluorouracil 22-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 134-139 11748447-4 2002 Introduction of HER-2 oncoprotein in vitro induces resistance to several anticancer drugs, including taxanes, cisplatin (CDDP) and 5-fluorouracil (5-FU) in breast cancer cells. Fluorouracil 131-145 erb-b2 receptor tyrosine kinase 2 Homo sapiens 16-21 12973835-0 2003 ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Fluorouracil 212-226 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-5 12761490-4 2003 Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin). Fluorouracil 260-274 erb-b2 receptor tyrosine kinase 2 Homo sapiens 16-20 11872346-3 2002 The purpose of this study was to assess whether c-erbB-2 expression is associated with clinical sensitivity to docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF). Fluorouracil 156-170 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-56 11748447-4 2002 Introduction of HER-2 oncoprotein in vitro induces resistance to several anticancer drugs, including taxanes, cisplatin (CDDP) and 5-fluorouracil (5-FU) in breast cancer cells. Fluorouracil 147-151 erb-b2 receptor tyrosine kinase 2 Homo sapiens 16-21 11748447-7 2002 In contrast, a correlation between the response to a cyclophosphamide + methotrexate + 5-FU regimen and overexpression of HER-2 is not certain. Fluorouracil 87-91 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-127 11759828-2 2001 It was the purpose of this in vitro study to define the association between HER-2/neu overexpression and the sensitivity to the chemotherapeutic drug combinations of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and 5-fluorouracil, epirubicin and cyclophosphamide (FEC) of breast cancer cells derived from 140 chemotherapy-naive patients at the time of primary surgery. Fluorouracil 201-215 erb-b2 receptor tyrosine kinase 2 Homo sapiens 82-85 11759828-2 2001 It was the purpose of this in vitro study to define the association between HER-2/neu overexpression and the sensitivity to the chemotherapeutic drug combinations of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and 5-fluorouracil, epirubicin and cyclophosphamide (FEC) of breast cancer cells derived from 140 chemotherapy-naive patients at the time of primary surgery. Fluorouracil 226-240 erb-b2 receptor tyrosine kinase 2 Homo sapiens 82-85 12655533-0 2003 Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Fluorouracil 83-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-25 12655533-1 2003 BACKGROUND: The objective of this study was to determine whether HER-2 overexpression is associated with improved response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in patients with breast carcinoma. Fluorouracil 156-170 erb-b2 receptor tyrosine kinase 2 Homo sapiens 65-70 11236028-3 2000 Chemotherapy trials have supported an interaction between HER-2 overexpression and chemotherapy sensitivity (cyclophosphamide/methotrexate/5-fluorouracil resistance and doxorubicin sensitivity) which is compelling. Fluorouracil 139-153 erb-b2 receptor tyrosine kinase 2 Homo sapiens 58-63 11121461-2 2000 This has led some clinicians to propose that HER2 should be used as a predictive marker in choosing between anthracycline-based regimens and combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). Fluorouracil 207-221 erb-b2 receptor tyrosine kinase 2 Homo sapiens 45-49 11208823-0 2001 Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. Fluorouracil 48-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 11208823-3 2001 However, the significance of HER2 overexpression in responsiveness to cyclophosphamide, methotrexate, and fluorouracil (CMF) has remained unclear. Fluorouracil 106-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 29-33 11694791-5 2001 It has not yet been demonstrated conclusively that HER2 positivity increases resistance to adjuvant cyclophosphamide, methotrexate, 5-FU (CMF), but there are indications that HER2-positive patients benefit more from adequately dosed anthracyclines than from CMF. Fluorouracil 132-136 erb-b2 receptor tyrosine kinase 2 Homo sapiens 51-55 12849612-12 2000 It is also possible that HER2-overexpressing patients may respond better to dose-intense anthracycline therapy and worse to cyclophosphamide/methotrexate/5-fluorouracil than non-overexpressing patients. Fluorouracil 154-168 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-29 10623878-6 2000 HER2 overexpression is associated with breast cancer patient responsiveness to doxorubicin, to cyclophosphamide, methotrexate, and fluorouracil (CMF), and to paclitaxel, whereas tamoxifen was found to be ineffective and even detrimental in patients with HER2-positive tumors. Fluorouracil 131-143 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 10561274-4 1999 The genetic prodrug activation therapy is specifically targeted to erbB-2-overexpressing breast cancer cells by use of a therapeutic cassette that contains the Escherichia coli cytosine deaminase gene driven by the tumor-specific erbB-2 promoter, thus allowing activation of fluorocytosine to the active cytotoxic fluorouracil only within tumor cells that express the oncogene. Fluorouracil 314-326 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-73 10561274-4 1999 The genetic prodrug activation therapy is specifically targeted to erbB-2-overexpressing breast cancer cells by use of a therapeutic cassette that contains the Escherichia coli cytosine deaminase gene driven by the tumor-specific erbB-2 promoter, thus allowing activation of fluorocytosine to the active cytotoxic fluorouracil only within tumor cells that express the oncogene. Fluorouracil 314-326 erb-b2 receptor tyrosine kinase 2 Homo sapiens 230-236